Brought to you by 
Novartis purchases SB's Famvir and Vectavir/Denavir
07 Dec 2022
Executive Summary
In a deal worth $1.63bn, pharmaceutical conglomerate Novartis will acquire SmithKline Beecham's antiviral products Famvir (famciclovir) and Vectavir/Denavir (penciclovir). SB is divesting its antiviral line due to antitrust concerns in conjunction with its merger with Glaxo Wellcome.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis purchases SB's Famvir and Vectavir/Denavir
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice